TransCode Therapeutics
RNAZ----
Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: TransCode Therapeutics(RNAZ) the EBIT is -6.23 M (-47.59%);the EPS is -7.17 (-39.81%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.01B47.59%
----
----
EPS
-7.172239.81%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf